WallStreetZenWallStreetZen

NASDAQ: SXTC
China Sxt Pharmaceuticals Revenue

OverviewEarningsRevenue
DividendOwnership
China Sxt Pharmaceuticals revenue was $19.14k for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2024) ending on Sep 30, 2024 was N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Mar 31, 2024, SXTC annual revenue was $27.8k, with -17.4% growth year-over-year.

SXTC past revenue growth

How has SXTC's revenue growth performed historically?

Company
-36.02%
Industry
10.38%
Market
20.68%
SXTC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SXTC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SXTC's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SXTC revenue history

Current Revenue
$19.1k
Current Earnings
$5.8M
Current Profit Margin
30,275.6%

Be the first to know when SXTC announces revenue.

SXTC Revenue History By Year

SXTC Yearly RevenueSXTC RevenueSXTC ChangeSXTC Revenue Growth
2024-03-31$27.76k-$5.86k-17.43%
2023-03-31$33.62k-$305.51k-90.09%
2022-03-31$339.13k-$545.86k-61.68%
2021-03-31$884.99k$554.56k+167.83%
2020-03-31$330.43k$118.28k+55.75%
2019-03-31$212.16k-$1.10M-83.89%
2018-03-31$1.32M$585.53k+80.04%
2017-03-31$731.51kN/AN/A

1 of 1

China Sxt Pharmaceuticals Revenue FAQ

What was SXTC's revenue last quarter?

China Sxt Pharmaceuticals (NASDAQ: SXTC) reported Q3 2024 revenue of N/A up N/A year over year. In the same quarter last year, China Sxt Pharmaceuticals's revenue was N/A.

What was China Sxt Pharmaceuticals's revenue in 2024?

China Sxt Pharmaceuticals's annual revenue for the twelve months ending Mar 31, 2024 was $27.76 thousand, a 17.43% decrease year over year.

How much does China Sxt Pharmaceuticals make in a day?

Based on China Sxt Pharmaceuticals annual revenue for the past five years, SXTC makes an average of $885.44 per day.

What was China Sxt Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, China Sxt Pharmaceuticals's revenue has grown -36.02% year over year. This is 46.4 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.38%. China Sxt Pharmaceuticals's revenue in the past year totaled $19.14 thousand.

How much does China Sxt Pharmaceuticals make in a year?

China Sxt Pharmaceuticals's revenue by year for the past five years is:
  • China Sxt Pharmaceuticals's revenue for the twelve months ending Mar 31, 2024 was $27.76 thousand, a 17.43% decrease year over year.
  • China Sxt Pharmaceuticals's annual revenue for Mar 31, 2023 was $33.62 thousand, a 90.09% decrease from 2022.
  • China Sxt Pharmaceuticals's annual revenue for 2022 was $339.13 thousand, a 61.68% decrease from 2021.
  • China Sxt Pharmaceuticals's annual revenue for 2021 was $884.99 thousand, a 167.83% increase from 2020.
  • China Sxt Pharmaceuticals's annual revenue for 2020 was $330.43 thousand, a 55.75% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.